AI drug R&D company Absci (ABSI.US) receives $20 million investment from AMD (AMD.US)
Absci (ABSI.US) has secured a $20 million investment from AMD (AMD.US) in the form of a private equity investment (PIPE).
Artificial intelligence drug development company Absci (ABSI.US) has received a $20 million investment from AMD (AMD.US) in the form of a private placement of equity (PIPE).
At the time of writing, Absci's stock is up 46.58% in pre-market trading, at $4.50.
Absci has also announced a strategic partnership with AMD to deploy the latter's Instinct accelerators and ROCm software. This investment is expected to help AMD increase the usage of its artificial intelligence chips in the healthcare industry.
This investment in Absci marks AMD's first attempt to enter the life sciences field through its artificial intelligence chips. Absci will shift towards using more of AMD's GPUs.
The biotech company will use the funding from this investment to further build its artificial intelligence models and continue their internal drug development work.
Related Articles
EV Dynamics (00476) has completed the placement of a total of 27 million shares.
Shenzhen FRD Science & Technology (300602.SZ) actual controller terminates agreement to transfer partial shares of the company.
WEIGAO GROUP (01066) spent HK$353,400 to repurchase 60,000 shares on May 9th.
EV Dynamics (00476) has completed the placement of a total of 27 million shares.
Shenzhen FRD Science & Technology (300602.SZ) actual controller terminates agreement to transfer partial shares of the company.
WEIGAO GROUP (01066) spent HK$353,400 to repurchase 60,000 shares on May 9th.
RECOMMEND
General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025
Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025
Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025
